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ABSTRACT
Enterococcus faecalis and Streptococcus gallolyticus cause infective endocarditis (IE), which can originate from the continuous
release or translocation of low bacterial numbers into the bloodstream. In this context, IE cannot be prevented with
antibiotics. We previously demonstrated that aspirin plus ticlopidine protected rats from IE due to S. gordonii and
Staphylococcus aureus. Here we showed that aspirin plus ticlopidine significantly reduced vegetation weight and protected 73
and 64% rats (P < 0.005) from IE due to E. faecalis and S. gallolyticus, respectively. These results further support the potential
use of aspirin plus ticlopidine for a global prevention of IE in high-risk patients.
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Enterococcus faecalis and Streptococcus gallolyticus are important
etiologic agents of infective endocarditis (IE) in humans, with
high incidence in elderly people (Slipczuk et al. 2013). IE induced
by these bacteria is often caused by low-level bacteremia result-
ing from an infected medical device (Yagupsky and Nolte 1990;
Sandoe et al. 2002) or from continuous translocation in small
numbers from the gastrointestinal tract (Berg 1995).
New guidelines for IE prophylaxis restrict the use of antibi-
otics to high-risk patients, i.e. those with prosthetic valves or
with a history of IE and impending medical procedure with high
risk to contract bacteremia (Wilson et al. 2007). Nevertheless, the
new guidelines do not propose any valuable alternative for the
prevention of IE resulting from recurrent low-level bacteremia.
In this context, general protective strategies that do not involve
the use of antibiotics would greatly benefit at-risk patients (Chi-
rouze, Hoen and Duval 2012). Since platelets are key elements
in vegetation formation and growth, the use of antiaggregat-
ing agents appears a sensible strategy for IE prevention. We re-
cently demonstrated that the combination of the antiplatelet
oral drugs aspirin and ticlopidine was effective in the prophy-
laxis of experimental IE induced by S. gordonii and Staphylococcus
aureus (Veloso et al. 2015). Here we investigated the efficacy of
aspirin plus ticlopidine in the prophylaxis of IE induced in rats
by E. faecalis and S. gallolyticus.
Enterococcus faecalis JH2–2 (Yagi and Clewell 1980) and S. gal-
lolyticus UCN34 (Rusniok et al. 2010) were used. Isolates were
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grown at 37◦C with 5% CO2 in brain heart infusion broth or
agar (Difco; Becton Dickinson, Sparks, MD). Aspirin and ticlo-
pidine did not possess antimicrobial activity against the tested
strains, as they displayed minimal inhibitory concentrations of
>500 μg mL−1, values which abundantly exceed the pharmaco-
logically relevant concentrations.
Platelet-rich plasma (PRP) and platelet-poor plasma used for
the platelet-aggregation tests were obtained from anticoagu-
lated human blood as described previously (Veloso et al. 2013).
The ability of aspirin (50 μg mL−1), ticlopidine (2 μg mL−1) and
the combination thereof to inhibit the aggregation of E. faecalis
JH2–2 and S. gallolyticus UCN34 to human platelets was assessed
by light transmission (A600nm) using a fluorimeter Infinite 200 R©
Pro (Tecan, Salzburg, Austria), as previously described (Veloso
et al. 2015). Platelet response was monitored for a maximum of
20 min. Various inhibitors were compared with regard to the in-
terval between the addition of bacteria to the PRP suspension
and the onset of the aggregation response (lag time). Adenosine
diphosphate (ADP; 10 μM), a known inducer of platelet aggre-
gation, was used as a positive control. Two independent experi-
ments were performed in quadruplicate.
All animal studies were carried out in strict accordance with
the recommendations of the Swiss Federal Act on Animal Pro-
tection. All protocols for animal studies were reviewed and ap-
proved by the Cantonal Committee on Animal Experiments of
the State of Vaud, Switzerland (Permit Number: 879.9). A mix-
ture of ketamine (75mg kg−1) andmidazolam (5mg kg−1) anaes-
thetics was administered to the animals before any surgical pro-
cedure. The production of catheter-induced aortic vegetations
was performed in female Wistar rats, as described previously
(Veloso et al. 2015). Prophylaxis started immediately after the in-
sertion of the intracardiac catheter and lasted for 48 h. Aspirin
(8 mg kg−1) and ticlopidine (10 mg kg−1), alone or in combina-
tion, were administered by an intravenous bolus injection ev-
ery 12 h (Veloso et al. 2015). Control rats received saline. Forty
eight hours after starting prophylaxis, animals were inoculated
intravenously with 106 CFU of E. faecalis JH2–2 or S. gallolyticus
UCN34, progressively delivered at a pace of 0.0017mLmin−1 over
10 h (Veloso et al. 2015). Bacteria were inoculated continuously at
low concentrations in order to simulate a protracted, low-level
release of bacteria in the bloodstream from an intravenous in-
fected device (Yagupsky and Nolte 1990) or to a constant translo-
cation of low bacterial numbers from the gastrointestinal tract
(Berg 1995). Rats were sacrificed 24 h after inoculation. The car-
diac vegetations and spleens were sterilely removed, weighed
and processed as described elsewhere to determine the num-
ber of viable organisms (Veloso et al. 2015). The lower limits of
detection of bacterial growth were 2 and 1 log10 CFU g−1 of veg-
etation and spleen, respectively. Results of spleen cultures were
indicated as positive or negative growth.
The quantification of the lag time prior to platelet aggrega-
tion, the weights of the vegetations (expressed as mean ± stan-
dard deviation) and the mean bacterial counts of cardiac veg-
etations were compared by the one way analysis of variance
(ANOVA) with Tukey’s multiple comparisons test. The percent-
age of infected tissues was analysed by the Fisher’s exact test or
the Chi-square test. All statistical analyses were performedwith
GraphPad Prism software (version 6.05 for Windows; GraphPad
Software, La Jolla, CA, USA, www.graphpad.com). Differences
were considered significant when P < 0.05 by use of two-sided
significance levels.
In the absence of either bacteria or drug, the lag time to
platelet aggregation was >20 min, whereas in the presence of
ADP shrank to nearly 1 min. Enterococcus faecalis JH2–2 did not
induce platelet aggregation (time to aggregate >20 min), in line
with previous studies that showed that platelet aggregation
caused by E. faecalis is strain and donor dependent (Johansson
and Rasmussen 2013).
In contrast to E. faecalis JH2–2, S. gallolyticus UCN34 rapidly
induced platelet aggregation (lag time of 7.5 ± 1.7 min) with a
maximum value of 77%. Aspirin or ticlopidine alone did not af-
fect neither the lag time (8.3 ± 1.7 and 6.8 ± 0.9 min, respec-
tively) nor the maximum aggregation value (80 and 75%, respec-
tively) of S. gallolyticusUCN34. In contrast, the combination of as-
pirin and ticlopidine significantly increased the lag time to 19.8
± 0.4 min and inhibited maximum platelet aggregation to 11%
(P < 0.0001).
The efficacy of aspirin, ticlopidine and the combination
thereof to prevent experimental IE by E. faecalis and S. gallolyti-
cus is illustrated in Fig. 1. In animals challenged with E. faecalis
JH2–2, aspirin alone effectively decreased the vegetation weight
(P < 0.05) and prevented IE in 31% (4/13) of animals. Ticlopidine
alone failed to reduce both the vegetationweight and slightly re-
duced the incidence of infection (11% [1/9] sterile vegetations).
By contrast, the combination of aspirin and ticlopidine signif-
icantly reduced the vegetation weight (P < 0.0001) and effec-
tively prevented IE in 73% (8/11) of animals (P = 0.001). Bleeding
events occurred only in one animal receiving aspirin. In animals
challenged with S. gallolyticus, aspirin reduced, albeit not sig-
nificantly, the vegetation weight and prevented IE in 20% (2/10)
of rats while ticlopidine neither reduced the vegetation weight
nor prevented IE (10% [1/10] sterile vegetations). By contrast, the
combination of aspirin and ticlopidine significantly reduced the
vegetation weight (P < 0.001) and effectively prevented IE (63%
[7/11] of sterile vegetations; P < 0.001). No bleeding events were
observed. Mean (log10 CFU g−1) bacterial counts in vegetations of
control, aspirin, ticlopidine and aspirin plus ticlopidine groups
were 7.03, 4.84 (P < 0.05 vs controls), 5.00 and 2.89 (P < 0.05 vs all
the other groups) in rats challenged with E. faecalis JH2–2, and
7.25, 5.13 (P < 0.05 vs controls), 5.80 and 3.55 (P < 0.05 vs all
the other groups) in rats challenged with S. gallolyticus UCN34,
respectively. All (100%) the control animals presented positive
spleen cultures. Spleen cultures were also positive in 80–100% of
animals receiving aspirin or ticlopidine alone. Spleens from an-
imals receiving aspirin plus ticlopidine were all (100%) infected
upon challenge with E. faecalis JH2–2 while only 26% (3/11) were
positive upon challenge with S. gallolyticus UCN34 (P < 0.05 vs all
the other groups).
Bacterial-induced platelet aggregation plays an important
role in the development of IE. However, the mechanisms of in-
teraction between E. faecalis or S. gallolyticus and platelets are
not well defined (Fitzgerald, Foster and Cox 2006; Cox, Kerrigan
and Watson 2011). In this work, we report for the first time the
ability of S. gallolyticus to induce platelet aggregation. Previous
studies reported that E. faecalis and S. gallolyticus bind preferen-
tially to collagen and to a lower extent to fibrinogen and to fi-
bronectin (Sillanpaa et al. 2008; Johansson and Rasmussen 2013).
Thus, it is plausible that E. faecalis and S. gallolyticus interact with
platelets through the GPVI collagen receptor and to a lesser ex-
tent through the GPIIb/IIIa fibrinogen receptor (Michelson 2010).
Aspirin and ticlopidine inhibit platelet aggregation by block-
ing different effectors of the signal transduction pathway,
namely the cyclooxygenase 1 COX1 (an enzyme involved in
the thromboxane A2 [TXA2] biosynthesis) and the platelet re-
ceptor for ADP P2Y12, respectively (Michelson 2010). Therefore,
the inhibitory action of aspirin and ticlopidine occurs down-
stream of the activating signals transmitted by the interac-
tions between bacteria and platelets, presumably through the
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Figure 1. Effect of prophylaxis with aspirin (ASA) and ticlopidine (TCL), alone or in combination, on both the weight of vegetations (A and B) and the prevention of
experimental endocarditis (C and D) induced by E. faecalis JH2–2 and S. gallolyticus UCN41. In panels A and B, each dot represents the vegetation weight for each animal
and the mean is represented by the solid line. The total number of animals is indicated at the bottom of each column in panels C and D. ∗P < 0.05 compared to the
control group by the ANOVA with Tukey’s correction test (vegetation weight). ∗∗P < 0.05 compared to all the other groups using the ANOVA with Tukey’s correction test
(vegetation weight), or using either the Fisher’s exact or the Chi-square tests (infected vegetations).
blockage of platelet-to-platelet interactions. In this study, as-
pirin and ticlopidine were given prophylactically, i.e. prior to
bacterial inoculation. This strategy likely resulted in decreased
formation of the nascent platelet/fibrin vegetations, which de-
prived circulating bacteria of a binding scaffold, necessary first
to adhere to the vegetations and then to promote their devel-
opment. However, additional effects of the drugs other than tar-
geting platelet receptors, i.e. the ability of aspirin to protect the
endothelium from oxidative stress and the antiinflammatory ef-
fect of ticlopidine, might also contribute to protection of the an-
imals from IE (Veloso et al. 2015).
The present results might have major clinical implications
in regard of prevention against E. faecalis and S. gallolyticus IE.
As an example, antiplatelet therapy is commonly used for the
prevention of cardiovascular and cerebrovascular diseases in el-
derly patients, a population with high incidence of IE due to E.
faecalis and S. gallolyticus (Slipczuk et al. 2013). The implementa-
tion of aspirin and ticlopidine (or equivalent newer molecules),
which can be administered orally for prolonged periods, might
contribute to reduce the incidence of both E. faecalis and S. gal-
lolyticus IE in this population.
Importantly, the use of antiplatelets, given before the emer-
gence of IE (rather than after IE establishment), is not associ-
ated with an increased risk of embolism in case of late IE, which
might compromise the validity of this treatment (Anavekar et al.
2007, 2011; Eisen et al. 2009). Likely, early antiaggregant therapy
may decrease the size of nascent vegetations and impede their
further enlargement, whereas late antiaggregant therapy might
favour vegetation dislodgment and bleeding in embolized areas
(Chan et al. 2003). The present findings further support the po-
tential beneficial use of antiplatelet agents for the prevention of
IE in humans.
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